These mechanistic understandings along with the reported clinical observations prompt us to test the hypothesis that co-targeting tumor-derived soluble NKG2D ligands would enhance melanoma tumor response to PD/PDL1 blockade therapy. Here, KLRK1 is linked to neoplasm.